Mircera gets FDA nod, but blocked by patent case

The FDA has approved Roche's anemia drug Mircera, but don't look for any big new product launches soon. Last month Amgen won a patent infringement case on the therapy. And Roche is studying its options--including a possible appeal of the case. In the meantime, Mircera is already available in a long lineup of countries that include Sweden, Germany and the UK.

- see Roche's release
- read the AFX report on Mircera

Related Articles:
Amgen wins patent fight with Roche. Report
Roche: Patent ruling won't stop Mircera. Report
Roche to Launch Mircera in U.K. and Germany. Report
FDA wants more data on new Aranesp doses. Report